The New Trend of Anti-Obesity Drug
|
|
- Barbra Perkins
- 5 years ago
- Views:
Transcription
1 2016 년대한당뇨병학회춘계학술대회 The New Trend of Anti-Obesity Drug MIN-SEON KIM ASAN MEDICAL CENTER
2 Conflict of Interest Nothing to declare
3 Index Introduction: Obesity Epidemiology, Pathophysiology and Comorbidity Endocrine society clinical practice guideline History of anti-obesity drugs Anti-obesity drugs currently approved by FDA Lorcaserin (BELVIQ) Phentermine/topiramate (Qsymia) Naltrexone/bupropion (Contrave) Liraglutide (Saxenda)
4 Trends in prevalence of BMI categories (Men) (Women) Men Women NCD Risk Factor Collaboration, Lancet, 2016
5 Prevalence of obesity (Korea) Total Male Female
6 Prevalence of obesity in DM patients (KDA fact sheet)
7 Physiological Impact of Obesity
8 Obesity T2DM 당뇨병발병위험 : 비만남성은 7 배, 비만여성은 12 배높다. Guh DP, BMC public health, 2009, 9:88
9 Obesity insulin resistance Free fatty acid Adipokine Leptin Adiponectin Resistin TNF- IL-6 PAI-1 Fatty liver Gluconeogenesis Glucose utilization Insulin secretion vascular dilatation
10 Obesity inflammation insulin resistance!
11 Obesity inflammation CVD
12 Weight reduction and health benefits Pharmacological management of obesity, J Clin Endocrinol Metab, 2015
13 Endocrine Society Clinical Practice Guideline Recommendation Diet, exercise, and behavioral modification : BMI 25 kg/m2 Pharmacotherapy and behavioral modification : BMI 30 kg/m2 or BMI 27 kg/m2 with comorbidity (HTN, dyslipidemia, T2DM and OSA) Bariatric surgery with behavioral modification : BMI 40 kg/m2 or BMI 35 kg/m2 with comorbidity (HTN, dyslipidemia, T2DM and OSA) Assessment of efficacy and safety of weight loss medication : at least monthly for the first 3 months at least every 3 months If deemed effective (weigt loss 5 % of body weight at 3 mo), continue If deemed ineffective (weight loss <5% at 3 mo), discontinue or consider alternative treatment
14
15
16 Lorcaserin (BELVIQ)
17 Mechanism of Lorcaserin
18 J Pharmacol Exp Ther May;325(2): Development of Lorcaserin 5-HT agonist weight loss 5-HT 2C Selective 5-HT2C agonist AE 5HT2B agonist CV Disease (Sibutramine) 5-TH 2A agonist Hallucinate Lorcaserin hydrochloride ( BELVIQ ) is a selective Serotonin 2C receptor agonist
19 Clinical trials BLOOM : Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management.(N Engl J Med 2010 ; 363(3) : ) BLOSSOM : A One-year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults : The BLOSSOM Trial (J Clin Endocrinol Metab 2011 ; 96(10) : ) BLOOM-DM : Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study. (Obesity 2012 ; 20 : ) Title Enrolled Duration overweight adults with type 2 DM BLOOM 3,182 2 year Excluded BLOSSOM 4,008 1 year Excluded BLOOM-DM year Included
20 BLOOM Double blind, RCT 3182 명을대상으로한대규모임상시험. BELVIQ 의 2 년안전성및효과입증.
21 BLOOM - protocol Duration 2 years (year 1 weight loss, year2 maintenance of weight loss) Patients Age of 18 to 65 years, total 3,182patients. BMI of 30 to 45 or of 27 to 45 with at least 1 coexisting condition (hypertension, dyslipidemia, cardiovascular disease, impaired glucose tolerance, or sleep apnea). Instruction Return to the research site 2 and 4 weeks. Exercise moderately for 30 minutes daily and to reduce the daily calorie intake to 600 kcal N Engl J Med 2010 ; 363(3) :
22 BLOOM protocol Dose < year 1> BELVIQ 10mg BID (n=1595) < year 2> BELVIQ 10mg BID (n=573) Placebo (n=283) Placebo (n=1587) Placebo (n=697) N Engl J Med 2010 ; 363(3) :
23 BLOOM weight change year1 BELVIQ Placebo Lost of 5% of body weight Patients (%) *** 66.4% Lost of 10% of body weight Patients (%) *** p<0.001 *** 36.2% *** p< % 13.6% N Engl J Med 2010 ; 363(3) :
24 BLOOM weight change year1 BELVIQ Placebo Weight change (%) -3.3 *** p<0.001 (ITT) -8.1 *** N Engl J Med 2010 ; 363(3) :
25 BLOOM weight change year1,2 BELVIQ Placebo Weight change (kg) 감량체중유지환자 (%) *** *** p< % 50.3% BELVIQ BELVIQ BELVIQ Placebo N Engl J Med 2010 ; 363(3) :
26 BLOOM secondary endpoint Placebo BELVIQ p value Fasting glucose (mg / dl) < Blood Pressure (mm Hg) Systolic Diastolic Heart rate (beats per min) N Engl J Med 2010 ; 363(3) :
27 BLOOM safety year1,2 B = BELVIQ // P = Placebo Year 1 Year 2 B P B B B P P P Headache Upper respiratory infection Dizziness Nausea Dry mouth Constipation N Engl J Med 2010 ; 363(3) :
28 BLOOM safety year1,2 Incidence of Valvulopathy at Week 104 N Engl J Med 2010 ; 363(3) :
29 BLOOM-DM Behavioral Modification and Lorcaserin for Overweight and Obesity Management Diabetes Mellitus Double blind, RCT 604 명의비만인제 2 형당뇨환자를 대상으로함. 비만한당뇨환자에게 BELVIQ 의투약은체중조절및혈당조절 에도도움을준다는것이입증된시험. Obesity 2012 ; 20 :
30 BLOOM-DM Duration Patients 1 year Age of 18 to 65 years, total 604 patients. Patients were treated with metformin, a sulfonylurea (SFU) or both; had glycated hemoglobin (HbA1c) 7 10%; had BMI Instruction Return to the research site 2 and 4 weeks. Exercise moderately for 30 minutes daily and to reduce the daily calorie intake to 600 kcal Dose 10mg BELVIQ BID n=256 // 10mg BELVIQ QD n=95 // Placebo n=253 Obesity 2012 ; 20 :
31 BLOOM-DM weight change BELVIQ bid BELVIQ qd Placebo Lost of 5% of body weight Patients (%) *** *** 44.6% 54.7% *** p< % Lost of 10% of body weight Patients (%) *** 20.8% *** 22.7% *** p< % Obesity 2012 ; 20 :
32 BLOOM-DM weight change Weight change (%) - 1.5% - 1.7% - 4.5% *** - 5.5% *** - 5.5% *** - 5.8% *** *** p<0.001 *** p<0.001 Obesity 2012 ; 20 :
33 BLOOM-DM secondary endpoint Placebo BELVIQ QD p value BELVIQ BID p value Glycemic parameters Fasting glucose (mg/dl) HbA1c (%) P< P< P< P<0.001 Obesity 2012 ; 20 :
34 BLOOM-DM safety Obesity 2012 ; 20 :
35 Phentermine/topiramate (Qsymia)
36 Phentermine (PHEN) 아드레날린성식욕억제제 Phentermine 은시상하부에서에피네프린분비를촉진하고, 식사섭취량을감소시켜체중감소를촉진함. Serotonine 효과는없음 년 FDA 는단독요법으로일일 37.5 mg 이하용량으로단기간사용한다는조건으로 phentermine 의비만치료적응증을인정함.
37 Topiramate (TPM) Topiramate 단독요법은 1996 년간질발작치료적응승인, 2004 년편두통예방승인. 그러나체중관리목적만을위한단독요법은아직허가받지못함. Topiramate 의체중감소기전은명확하지않음. 안전성문제 : 용량이증가할수록인지장애, 이상감각등중추신경계및말초신경계에다양한부작용유발. Topiramate 에 phentermine 을복합처방함으로써, topiramate 의용량을줄여부작용을낮추고, 항비만효과를강화시킨복합제형이개발됨. PHEN/TPM CR 는 2012 년 7 월 FDA 승인.
38 CONQUER Lancet 2011; 377: 대규모 3 상임상연구 CONQUER 연구는미국 93 개연구센터, 전연령대 (18-70 세 ) 2487 명대상 가장많은수의대상환자, SEQUEL 연구로연장 BMI kg/m 2, 2 개이상의대상성동반질환 ( 고혈압, 고지혈증, 당뇨병및당뇨병전단계, 복부비만 ) 을가진환자 위약군 : 일일 1 회 PHEN 7.5 mg/ TPM 46.0 mg : PHEN 15 mg/ TPM 92.0 mg = 2:1:2 비율무작위배정
39 Effect of PHEN/TPM on body weight
40 Adverse events in the safety population
41 SEQUEL 2012 Feb;95(2): SEQUER 연구는항비만약제의장기복용효과를보고자, CONQUER 연구를연장하여총 108 주간의약물효과를조사 676 명의대상환자중이기간을마친환자는 84% 라는높은수치 3 개군에서큰차이가없었음
42 Mean (95% CI) percentage weight loss from baseline to week 108
43 Effects of PHEN/TPM CR on metabolic variables
44 All adverse events with frequency of 5% in any PHEN/TPM CR group
45 Naltrexone/bupropion (Contrave)
46 Naltrexone/bupropion Naltrexone 은중추신경계존재하는 opioid 수용체억제제. 알코올중독이나마약중독의치료제로 FDA 승인을받음. Naltrexone 은내인성 opioid 에의한 POMC 뉴런의억제를차단함으로써결과적으로 POMC 뉴런의흥분성을증가시켜식욕을줄이고음식섭취를줄임. Bupropion 은시냅스에서도파민 / 노르에피네프린의재흡수를방해하는약물. 항우울제혹은금연치료제로 FDA 승인을받음. Bupropion 은뇌에서세로토닌과도파민의수치를증가시켜음식섭취량을감소시키고, 에너지소비를증가시켜체중감소를유도함. Naltrexone SR/bupropion SR 는 2014 년 9 월 FDA 승인.
47 COR-I 대규모 3 상임상시험, 유럽의 34 개지역 1,742 명의성인 BMI kg/m² 이거나고지혈증또는고혈압을동반한 BMI kg/m² 인사람 위약 : NB32 (naltrexone 32 mg/bupropion 360 mg) : NB16 (naltrexone 16 mg/bupropion 360 mg) = 1 : 1 : 1 비율로무작위배정
48 Effect of Contrave on body weight
49 Adverse events in the safety population
50 COR-II COR-I 의후속연구 1,496 명의성인 BMI kg/m² 이거나고지혈증또는고혈압을동반한 BMI kg/m² NB32 (naltrexone 32 mg/bupropion 360 mg) : 위약 = 2 : 1 비율로무작위배정
51 COR-BMOD Behavior modification (BMOD) 을동반한 Contrave 치료효과 793 명의성인 위약 + BMOD : NB32 + BMOD = 1 : 3 비율로무작위배정
52 Liraglutide (Saxenda)
53 당뇨병치료제인 Victoza 는 liraglutide 1.2 mg, 1.8 mg 제형 비만치료제인 Saxenda 는 liraglutide 3 mg 주사제형, 1 일 1 회투여
54 SCALE Obesity and Prediabetes 대규모임상 3 상연구 당뇨가없는비만환자 3,731 명대상 BMI 30 kg/m 2 이거나고지혈증또는고혈압을가진 27 kg/m 2 인사람 일일 1 회 liraglutide 3.0 mg : 위약군 = 2 : 1 비율로무작위배정
55 Effect of liraglutide on body weight
56 Liraglutide and glucose levels during oral glucose-tolerance test and glycemic status
57 Adverse events in the study population
58 Thank you
Understanding Obesity: The Causes, Effects, and Treatment Options
Understanding Obesity: The Causes, Effects, and Treatment Options Jeffrey Sicat, MD, FACE Virginia Association of Clinical Nurse Specialists September 29, 2017 Objectives By the end of this discussion,
More informationLorcaserin (Belviq ) Rimonabant 2008 Sibutramine (Reductil, ) (World Health organization, WHO) 1996 WHO Orlistat (Xenical, )
(World Health organization, WHO) 1996 WHO (Body mass index, BMI)2427 kg/m 2 27 kg/m 2 25% 30%2013-2014 43.5%(48.9%38.3%) (AACE/ACE)2016 1 BMI 27 kg/m 2 BMI 35 kg/m 2 (The Food and Drug Administration,
More informationAn Individualized Approach to Optimize Obesity Treatment Louis Aronne, MD
An Individualized Approach to Optimize Obesity Treatment Louis Aronne, MD Sanford I. Weill Professor of Metabolic Research Director of the Comprehensive Weight Control Program Weill Cornell Medical College
More informationObesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, :15 a.m. 11:00 a.m.
Obesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, 2018 10:15 a.m. 11:00 a.m. Type 2 diabetes mellitus (T2DM) is closely associated with obesity, primarily through the link
More informationWhat Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels?
What Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels? Daniel Bessesen, MD Professor of Medicine University of Colorado School of Medicine Chief of Endocrinology,
More informationWEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM?
WEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM? THE OBESITY MEDICINE ASSOCIATION S DEFINITION OF OBESITY Obesity is defined as a chronic, relapsing, multi-factorial, neurobehavioral disease, wherein
More informationFaculty/Presenter Disclosure
Weight loss & Obesity WHAT S NEW & EXCITING? Tina Korownyk Dept of Family Medicine, UofA Faculty/Presenter Disclosure Faculty/Presenter: Tina Korownyk Relationships with commercial interests: None 1 Drowning
More information1 Mechanick JI, Garber AJ, Handelsman Y, Garvey WT. Endocr Pract. 2012;18: Depression. Cancer. Gallbladder Disease
Percent 4 3 2 1 Obese Overweight Extremely obese Note: Age-adjusted by the direct method to the year 2 US Bureau of the Census using age groups 2 39, 4 59, and 6 74 years. Pregnant females excluded. Overweight
More informationOBESITY IN TYPE 2 DIABETES
OBESITY IN TYPE 2 DIABETES Ashley Crowl, PharmD, BCACP Assistant Professor University of Kansas Objectives Review how to manage obesity in patients with type-2 diabetes mellitus Compare antiobesity agents
More informationMEDICAL MANAGEMENT 101
MEDICAL MANAGEMENT 101 Christopher Still, DO, FACN, FACP Medical Director, Center for Nutrition & Weight Management Director, Geisinger Obesity Research Institute Geisinger Health Care System Your Weight
More informationManagement of Obesity. Objectives. Background Impact and scope of Obesity. Control of Energy Homeostasis Methods of treatment Medications.
Medical Management of Obesity Ben O Donnell, MD 1 Objectives Background Impact and scope of Obesity Control of Energy Homeostasis Methods of treatment Medications 2 O'Donnell 1 Impact of Obesity According
More informationDonna H Ryan, MD, FACP Pennington Biomedical Research Center Baton Rouge, LA.
Donna H Ryan, MD, FACP Pennington Biomedical Research Center Baton Rouge, LA Donna.Ryan@pbrc.edu National Summit on Health Disparities April 22, 2013 Disclosure Dr. Ryan has served as an advisor to Nutrisystem
More informationDiabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
More informationAnti-Obesity Agents Drug Class Prior Authorization Protocol
Anti-Obesity Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: March 1, 2018 This policy has been developed through review
More informationFor Personal Use Only. Any commercial use is strictly prohibited. Role of glucagon-like peptide 1 receptor agonists in management of obesity
Role of glucagon-like peptide 1 receptor agonists in management of obesity Diana Isaacs, Pharm.D., BCPS, BC-ADM, CDE, Chicago State University, Chicago, IL, and Oak Lawn VA Clinic of Edward Hines Jr. VA
More information3/11/2019. Debate: A Conversation on Weight Management and Health at Every Size. Defining Obesity. Obesity: In the top three global social burdens
Foundational Concepts Debate: A Conversation on Weight Management and Health at Every Size Robert F. Kushner, MD, MS Professor of Medicine Northwestern University Feinberg School of Medicine Director,
More informationTreating Patients with PRE- DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background
Treating Patients with PRE- DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence
More informationWhen Diet and Exercise Aren t Enough: Pharmacologic Management of Obesity
When Diet and Exercise Aren t Enough: Pharmacologic Management of Obesity Casey Bonaquist, DO Saturday, April 30 th, 2016 17 th Annual Primary Care & Cardiovascular Symposium Learning Objectives After
More informationObesity: Pharmacologic and Surgical Management
Obesity: Pharmacologic and Surgical Management ADRIENNE YOUDIM, MD, FACP ASSOCIATE PROFESSOR OF MEDICINE, UCLA ASSISTANT PROFESSOR OF MEDICINE, CEDARS SINAI MEDICAL CENTER JANUARY 2018 Defining Obesity
More informationNew Drug Targets for the Treatment of Obesity
nature publishing group New Drug Targets for the Treatment of Obesity AG Powell 1, CM Apovian 2 and LJ Aronne 3 There is a huge void in the current pharmacological treatment options for obesity. This gap
More informationObesity Pharmacotherapy: Options and Applications in Clinical Practice. Scott Kahan, MD, MPH
Obesity Pharmacotherapy: Options and Applications in Clinical Practice Scott Kahan, MD, MPH Obesity Pharmacotherapy Few providers prescribe pharmacotherapy. Few patients use pharmacotherapy. Pharmacotherapy
More informationExamining the Value Proposition of Emerging Therapies and Treatment Models for. Faculty
Examining the Value Proposition of Emerging Therapies and Treatment Models for Obesity and Weight Management Faculty Robert F. Kushner, MD, MS, FACP Professor of Medicine Clinical Director Northwestern
More informationLearning Objectives. Currently Available Options. Update on Weight Loss Pharmacotherapy. Dan Bessesen, MD
Update on Weight Loss Pharmacotherapy Dan Bessesen, MD Daniel.bessesen@ucdenver.edu Learning Objectives List the medications that are currently available for the treatment of obesity, describe their mechanisms
More informationHealthy weight 18.5 to <25. Diabetes Dispatch. Overweight 25 to <30. Obese class I 30 to <35. Obese class II 35 to <40
A L A S K A N A T I V E D I A B E T E S T E A M Diabetes Dispatch Volume 10, Issue 4 Winter 2015 T he American Medical Association, the World Health Organization, and the US Food and Drug Administration
More informationWHAT S THE SKINNY ON WEIGHT LOSS MEDICATION SAFETY? January 25, 2019 Pennsylvania Pharmacists Association
WHAT S THE SKINNY ON WEIGHT LOSS MEDICATION SAFETY? January 25, 2019 Pennsylvania Pharmacists Association MEGAN N DUNLOP, PHARMD, CTTS CLINICAL PHARMACIST, UPMC COMMUNITY PROVIDER SERVICES LEARNING OBJECTIVES
More informationThe ABCDs of Obesity
The ABCDs of Obesity Adipose Based Chronic Disease Michael A. Bush, M.D. Clinical Chief, Division of Endocrinology Cedars-Sinai Medical Center Clinical Associate Professor, Geffen School of Medicine, UCLA
More informationObesity Treatment Update
Southern States Chapter of the American Association of Clinical Endocrinologists 2013 Annual Meeting Obesity Treatment Update Caroline M. Apovian, MD, FACN, FACP Director, Center for Nutrition and Weight
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1172-3 Program Prior Authorization - California and New York Regulatory Program - Weight Loss Medication Includes both brand and
More informationModest weight loss of 5% to 10%
These 4 cases illustrate how weight loss drugs including the 4 newest can be integrated into a treatment plan that includes diet, exercise, and behavior modification Katherine H. Saunders, MD; Alpana P.
More informationSyllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes.
1:55-2:4pm Medical Management of Obesity: Lifestyle, Medicine, and Surgery SPEAKER Osama Hamdy, MD, PhD, FACE Disclosures The following relationships exist related to this presentation: Osama Hamdy, MD,
More informationPrediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes!
Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Jaini Patel, PharmD, BCACP Assistant Professor of Pharmacy Practice Midwestern University Chicago College of Pharmacy Kathleen
More informationPharmacotherapy III: Naltrexone/Bupropion(Contrave ) for Chronic Weight Management. Renuca Modi MD CCFP 2 nd ANNUAL OBESITY UPDATE September 22, 2018
Pharmacotherapy III: Naltrexone/Bupropion(Contrave ) for Chronic Weight Management Renuca Modi MD CCFP 2 nd ANNUAL OBESITY UPDATE September 22, 2018 COI Faculty: Renuca Modi, MD, CCFP Diplomate of the
More informationPrediabetes Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Disclosures/Conflict of Interest.
Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Jaini Patel, PharmD, BCACP Assistant Professor of Pharmacy Practice Midwestern University Chicago College of Pharmacy Kathleen
More informationFDA approves Belviq to treat some overweight or obese adults
FDA approves Belviq to treat some overweight or obese adults Silver Spring, MD, USA (June 27, 2012) - The U.S. Food and Drug Administration today approved Belviq (lorcaserin hydrochloride), as an addition
More informationDisclosures. Start the Conversation. Agenda. Behavioral and Medical Approaches for Obesity Treatment 10/18/2014
Disclosures Behavioral and Medical Approaches for Obesity Treatment Scott Kahan, MD, MPH Director, National Center for Weight and Wellness Clinical Director, Strategies To Overcome and Prevent (STOP) Obesity
More informationA Heavy Burden: Obesity and Diabetes" Diabetes In and Out University of Rochester School of Medicine and Dentistry March 12, 2016
A Heavy Burden: Obesity and Diabetes" Diabetes In and Out University of Rochester School of Medicine and Dentistry March 12, 2016 Robert H. Eckel, M.D. Professor of Medicine Professor of Physiology and
More informationTreatment of Obesity SAJIDA AHAD MERCY GENERAL SURGERY
Treatment of Obesity SAJIDA AHAD MERCY GENERAL SURGERY Objectives 1. Learn classification and evaluation of overweight and obese patient 2. Discuss impact of voluntary weight loss on morbidity and mortality
More informationFor Asian individuals the BMI numbers are 27.5 and 25 respectively These values are from the NICE guidelines of 2014
Ken Cathcart DO FACE We need to define several things to start the talk Obesity is defined medically as a BMI of greater than 30 or a BMI >27 with co-morbidities such as hypertension, type 2 DM, dyslipidemia,
More informationManagement of obesity
From Behavior Modification through Pharmacotherapy to Surgery an Emphasis on the Team Approach Scott D. Isaacs, M.D., F.A.C.P., F.A.C.E. drisaacs@atlantaendocrine.com Understand the physician s role in
More informationPharmacotherapy IV: Liraglutide for Chronic Weight Management SARAH CAWSEY MD, FRCPC 2 ND ANNUAL OBESITY UPDATE SEPTEMBER 22, 2018
Pharmacotherapy IV: Liraglutide for Chronic Weight Management SARAH CAWSEY MD, FRCPC 2 ND ANNUAL OBESITY UPDATE SEPTEMBER 22, 2018 Disclosures Faculty Assistant Clinical Professor, Department of Medicine,
More informationOverweight and Obesity on the Menu. Marwan Akel, Pharm. D, MPH Clinical Assistant Professor School of Pharmacy Lebanese International University
Overweight and Obesity on the Menu Marwan Akel, Pharm. D, MPH Clinical Assistant Professor School of Pharmacy Lebanese International University Prevention The most efficient and cost-effective approach
More informationPast, Present and Future of Pharmacotherapy for Obesity
Past, Present and Future of Pharmacotherapy for Obesity Dan Bessesen, MD Chief of Endocrinology; Denver Health Medical Center Professor of Medicine, University of Colorado School of Medicine Daniel.Bessesen@ucdenver.edu
More informationManaging Obesity as a Disease. Disclosure. Objectives
Managing Obesity as a Disease Ji Hyun Chun (CJ), PA-C, BC-ADM OptumCare Medical Group: Endocrinology, Irvine, CA President, American Society of Endocrine PAs none Disclosure Objectives Recognize obesity
More informationObesity Management in Type 2 Diabetes
Obesity Management in Type 2 Diabetes Clare J. Lee, MD, MHS Assistant Professor of Medicine, Division of Endocrinology, Diabetes & Metabolism, Johns Hopkins University Disclosures None Objectives Describe
More informationSystem): Rapid-Acting Inhaled Insulin for the Treatment of Diabetes
Volume 30, Issue 2 November 2014 Afrezza (Technosphere Insulin Inhalation System): Rapid-Acting Inhaled Insulin for the Treatment of Diabetes Merly Suarez, PharmD Candidate D P PharmacodynamicsandPharmacokinetics
More informationReview of Pharmacologic Weight Loss Medications in a Patient-Centered Medical Home
604858PMTXXX10.1177/8755122515604858Journal of Pharmacy TechnologyCostello et al research-article2015 Case report Review of Pharmacologic Weight Loss Medications in a Patient-Centered Medical Home Journal
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationThe efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update
HORMONES 2015, 14(3):370-375 Review The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update Georgios A. Christou, Dimitrios N. Kiortsis Laboratory of Physiology,
More informationNEW DEVELOPMENTS IN ASSESSMENT AND TREATMENT OF OBESITY
Prevalence of Obesity (Adults)! Obesity: 33.8% Men: 32.2% Women: 35.5% Overweight + obesity: 68% Men: 72.3% Women: 64.1% Severe Obesity: 6% Flegal JAMA 2010 Men and Women Aged 40 to 59 Years in 1999-2000
More informationSafety and Tolerability of Medications Approved for Chronic Weight Management
19. Gadde KM, Allison, DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in
More informationBeyond A1C. Non-glycemic Effects of GLP-1 Receptor Agonists. Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows
Beyond A1C Non-glycemic Effects of GLP-1 Receptor Agonists Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows Disclosures No conflicts of interest. Learning Objectives 1. Understand the physiological
More informationAnti-Obesity Drugs - Current Status & Application in Diabetic Patients - 순천향의대부천병원 내분비내과 김철희
Anti-Obesity Drugs - Current Status & Application in Diabetic Patients - 순천향의대부천병원 내분비내과 김철희 Obesity Treatment Pyramid BMI Surgery Pharmacotherapy Lifestyle Modification Diet Physical Activity Selecting
More informationLet s s start with a case study.
Disclosure Dr. Ryan has received financial remuneration in 2015 from Amgen, Novo Nordisk, Janssen, Pfizer, Takeda, Vivus, Real Appeal, and Scientific Intake. Medicating the Patient with Obesity Clinical
More informationGoals for Medical Treatment in Obesity and Prediabetes: Improving Outcomes
Goals for Medical Treatment in Obesity and Prediabetes: Improving Outcomes Leigh Perreault, MD Associate Professor of Medicine Endocrinology, Metabolism and Diabetes University of Colorado Anschutz Medical
More informationObesity is a major public health concern in all of the
CASE REPORT Saxenda in the Management of Obesity in a Type 2 Diabetes Mellitus Patient: A Case Report Gilles Plourde 1,2 1 Department of Clinical Pharmacology and Physiology, Faculty of Medicine, University
More informationBrand Name: Belviq. Generic Name: lorcaserin hydrochloride. Manufacturer 3 : Eisai Inc. Drug Class 1,2 : Serotonin 5-HT 2C Receptor Agonist
Brand Name: Belviq Generic Name: lorcaserin hydrochloride Manufacturer 3 : Eisai Inc. Drug Class 1,2 : Serotonin 5-HT 2C Receptor Agonist Uses: Labeled Uses 1,2,3,4,5 : Adjunctive treatment for obesity
More informationCURRENT STRATEGIES IN OBESITY
Prevalence of Obesity (Adults)! Obesity: 33.8% Men: 32.2% Women: 35.5% Overweight + obesity: 68% Men: 72.3% Women: 64.1% Severe Obesity: 6% Flegal JAMA 2010 Men and Women Aged 40 to 59 Years in 1999-2000
More informationDiabesity: Treatment Options for an Epidemic of Growing Proportions
Diabesity: Treatment Options for an Epidemic of Growing Proportions www.freedigitalphotos.net Jennifer Poehls, MD Clinical Assistant Professor UW School of Medicine and Public Health Section of Endocrinology,
More informationUpdate on Treating Obesity: A Multidisciplinary Approach. Marie Harkins, FNP BC, CDE Cayuga Center for Healthy Living
Update on Treating Obesity: A Multidisciplinary Approach Marie Harkins, FNP BC, CDE Cayuga Center for Healthy Living Objectives 1. Define obesity as a disease 2. List the stepwise approach to obesity treatment
More informationNon-surgical Treatment for Adult Obesity
Non-surgical Treatment for Adult Obesity Kathy Foreman, CNP Comprehensive Weight Management and Bariatric Surgery Program The Ohio State University Wexner Medical Center Objectives Definition, prevalence
More informationOverview of Management of Obesity
Overview of Management of Obesity Srividya Kidambi, MD, MS Division of Endocrinology, Metabolism, and Clinical Nutrition Medical College of Wisconsin, Milwaukee, WI I have nothing to disclose. Objectives
More informationRegulatory Hurdles for Drug Approvals
Regulatory Hurdles for Drug Approvals William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research 25 min Conflicts CPC Clinical Research
More informationPharmacotherapy of Obesity
C H A P T E R 157 Pharmacotherapy of Obesity Sachin Kumar Jain, Rati Singh, Ramesh Aggarwal, Ritika Sud INTRODUCTION Obesity has emerged as a global public health crisis and obesity rates have sharply
More informationCOMBINATION OF PHENTERMINE/TOPIRAMATE ER AND LIRAGLUTIDE 3MG FOR INTENSIVE THERAPY OF SEVERE OBESITY & T2DM A CASE SERIES AND BRIEF REVIEW
AACE Clinical Case Reports Rapid Electronic Articles in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited,
More informationAACE/ACE ALGORITHM FOR THE MEDICAL CARE OF PATIENTS WITH OBESITY
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AMERICAN COLLEGE OF ENDOCRINOLOGY AACE/ACE ALGORITHM FOR THE MEDICAL CARE OF PATIENTS WITH OBESITY O B E S I T Y R E S O U R C E C E N T E R CO M M I T
More informationPutting It in Perspective Using Medications for Chronic Weight Management. Donna H. Ryan, MD Pennington Biomedical Research Center
Putting It in Perspective Using Medications for Chronic Weight Management Donna H. Ryan, MD Pennington Biomedical Research Center ryandh@pbrc.edu Why Use Medications? Medications help patients lose more
More informationNaltrexone and Bupropion Combination: A New Promising Therapy for Long Term Weight Loss
Pacific University CommonKnowledge School of Physician Assistant Studies Theses, Dissertations and Capstone Projects Summer 8-8-2015 Naltrexone and Bupropion Combination: A New Promising Therapy for Long
More informationUpdate on the Recent Advances in Obesity Management. Benjamin O Donnell, MD Oct 5 th, 2018
Update on the Recent Advances in Obesity Management Benjamin O Donnell, MD Oct 5 th, 2018 Objectives Background Control of Energy Homeostasis Approach to Diet and Exercise Medications Recently Approved
More informationDepartment of Obstetrics and Gynecology, School of Medicine, Pusan National University, Busan, Korea
pissn: 2288-6478, eissn: 2288-6761 Review Article Pharmacotherapy for Obesity Jong Kil Joo, Kyu Sup Lee Department of Obstetrics and Gynecology, School of Medicine, Pusan National University, Busan, Korea
More informationControversies in Obesity Management
Controversies in Obesity Management A Technology Assessment Draft Appendices May 26, 2015 Completed by: Institute for Clinical and Economic Review AUTHORS: Daniel A. Ollendorf, PhD Chief Review Officer,
More informationDisclosures. Objectives. Impact of Obesity in Primary Care Practice and What To Do About It. Intuitive Surgical. Consultant
Disclosures Intuitive Surgical Consultant Stephen Archer, MD, FACS, FASMBS Director, Bariatric Surgery, St. Charles Medical Center Bend, OR Grand Rounds June 15, 2018 2 Objectives Impact of Obesity in
More informationEpidemic of Obesity: What Can We Do?
Epidemic of Obesity: What Can We Do? Theodore Feldman MD, FACC, FACP Medical Director Center for Prevention and Wellness Baptist Health South Florida Medical Director South Miami Heart Center Heartwell
More informationNaltrexone/Bupropion. Contrave Ò ; Naltrexone SR/Bupropion SR. Abstract. 1. Introduction
ADIS R&D PROFILE Drugs R D 2010; 10 (1): 25-32 1179-6901/10/0001-0025 ª 2010 Adis Data Information BV. All rights reserved. Naltrexone/Bupropion Contrave Ò ; Naltrexone SR/Bupropion SR Abstract In March
More informationPrevalence of Obesity (Adults) Prevalence of Obesity (Children) CURRENT STRATEGIES IN. Obesity: 33.8% Men: 32.2% Women: 35.5%
CURRENT STRATEGIES IN OBESITY Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Prevalence of Obesity (Adults) Obesity:
More informationTITLE: DATE: 9 July 2014 CONTEXT AND POLICY ISSUES
TITLE: Obesity Management Interventions Delivered in Primary Care for Patients with Hypertension or Cardiovascular Disease: A Review of Clinical Effectiveness DATE: 9 July 2014 CONTEXT AND POLICY ISSUES
More informationCopyright 2017 by Sea Courses Inc.
Appetite Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or mechanical,
More informationNavigating the new weight loss medications Jacqueline Jordan Spiegel, MS, PA-C, DFAAPA Associate Professor Midwestern University
Navigating the new weight loss medications Jacqueline Jordan Spiegel, MS, PA-C, DFAAPA Associate Professor Midwestern University Objectives Discuss the evolution of obesity as a diagnosis and disease.
More informationWhy Do We Treat Obesity? Metabolic Complications
Why Do We Treat Obesity? Metabolic Complications 2 Metabolic Complications of Obesity Diabetes Risk 3 Criteria for Diagnosis of the Metabolic Syndrome Characteristic Waist circumference Triglycerides HDL-C
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationClinical Policy: Weight Loss Reference Number: CP.CPA.197 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Reference Number: CP.CPA.197 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationControversies in Obesity Management
Controversies in Obesity Management A Technology Assessment Final Report Appendices August 10, 2015 Completed by: Institute for Clinical and Economic Review AUTHORS: Daniel A. Ollendorf, PhD Chief Review
More informationOBESITY: FACTS AND FICTIONS
Robert B. Baron MD MS Prevalence of Obesity (Adults) Obesity: 33.8% Men: 32.2% Women: 35.5% Professor of Medicine Associate Dean for GME and CME Director, UCSF Osher Mini Med School Director, UCSF Weight
More informationWhen Lifestyle Modification Therapy is Not Enough: Pharmacotherapy for Severe/Complicated Pediatric Obesity
When Lifestyle Modification Therapy is Not Enough: Pharmacotherapy for Severe/Complicated Pediatric Obesity Claudia Fox, MD MPH Diplomate, American Board of Obesity Medicine Medical Director, Pediatric
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationHypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital
Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI
More informationCAMBRIDGESHIRE JOINT PRESCRIBING GROUP DDECISION DOCUMENT Recommendation made by CJPG to Commissioners and Prescribers
CAMBRIDGESHIRE JOINT PRESCRIBING GROUP DDECISION DOCUMENT Recommendation made by CJPG to Commissioners and Prescribers Lorcaserin (Lorqess (US name), Arena pharmaceuticals) for obesity Date of last revision
More informationClinical Policy: Weight Loss Reference Number: CP.CPA.200 Effective Date: Last Review Date: Line of Business: Commercial - HNCA
Clinical Policy: Reference Number: CP.CPA.200 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial - HNCA Revision Log See Important Reminder at the end of this policy for important
More informationMedical Management of Obesity: Multidisciplinary Team and Pharmacologic Therapy. Shelby Sullivan University of Colorado School Of Medicine
Medical Management of Obesity: Multidisciplinary Team and Pharmacologic Therapy Shelby Sullivan University of Colorado School Of Medicine Disclosures Research Support / Grants R01DK094483-02 Klein/Mittendorfer
More informationTreatment Options for Obesity: Lifestyle and Pharmacotherapy
Treatment Options for Obesity: Lifestyle and Pharmacotherapy Daniel Bessesen, MD Professor of Medicine University of Colorado, School of Medicine Denver, Colorado USA Daniel.Bessesen@ucdenver.edu Question
More information23-Aug-2011 Lixisenatide (AVE0010) - EFC6014 Version number: 1 (electronic 1.0)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of metformin
More informationOBESITY 2008: DIET, EXERCISE, DRUGS, AND SURGERY
OBESITY 2008: DIET, EXERCISE, DRUGS, AND SURGERY Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest CLASSIFICATION OF OVERWEIGHT
More information2. Is the request for Alli, Xenical or Belviq? Y N. 3. Has the patient received 6 months or more of therapy? Y N
Prior Authorization MERC CARE PLA Weight Reduction Medications (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date.
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationDisclosures OBESITY. Overview. Obesity: Definition. Prevalence of Obesity is Rising. Obesity as a Risk Factor. None
Disclosures None OBESITY Florencia Halperin, M.D. Medical Director, Program for Management Brigham and Women s Hospital Instructor in Medicine, Harvard Medical School Overview Obesity: Definition Definition
More informationAPhA March 2016 Annual Meeting Obesity Cases
APhA March 2016 Annual Meeting Obesity Cases Case #1 Pam is a 47 yo obese Caucasian woman; grade school teacher with a history of HTN, HoTR, and depression who presents for her annual physical. CC: I m
More informationWhat s the Skinny?: An Update on Medications for Weight Management
What s the Skinny?: An Update on Medications for Weight Management Katura C. Bullock, PharmD, BCPS Associate Professor UNT System College of Pharmacy SESSION OBJECTIVES 1. Recognize the prevalence of obesity
More informationGalvus the most comprehensively studied DPP-4 inhibitor
Galvus the most comprehensively studied DPP-4 inhibitor! >7 000 patients enrolled in clinical studies! >4 00 patients exposed to Galvus >1 300 patients exposed 2 weeks >300 patients exposed for 104 weeks!
More informationCURRENT STRATEGIES IN MANAGEMENT OF OBESITY. Prevalence of Obesity (Adults)
CURRENT STRATEGIES IN MANAGEMENT OF OBESITY Robert B. Baron MD MS Professor of Medicine Associate Dean for GME and CME Director, UCSF Weight Management Program Declaration of full disclosure: No conflict
More informationThe prevalence of obesity in adults has doubled over the past 30 years
Obesity in America: Facts and Fiction MICHAEL G. PERRI, PhD Professor, Clinical and Health Psychology Interim Dean, College of Public Health and Health Professions University of Florida Overview: Key Questions
More information!"#$%&%'(!)*+'(,(&)%-!'(.#!%('"./0%(( /1#).!(&2()!(((
!"#%&%'(!)*+'(,(&)%-!'(.#!%('"./0%(( /1#).!(&2()!((( 26%5&"7%'( At the end of this presentation, participants should be able to: Evaluate the emerging role of GLP-1 Agonists for weight loss Understand
More information